Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) announced that its Phase 3 COMPASS PWS trial evaluating intranasal carbetocin (ACP-101) for hyperphagia in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE